Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...
Each adult in our IOP receives a personalized care plan that guides them through treatment. Patients participate in a variety of group therapies during each treatment day that cover topics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback